Strong growth capped by QoQ PAT collapse, slim underwriting margin

Retail 47.1% vs market 31.6%, difference 15.5 points

Q1 FY27: 100.2% vs Q1 FY26: 103.2%, exactly 300 bps improvement confirmed

No specific group growth % disclosed; management acknowledges zero growth due to pricing discipline

35% of retail GWP is fresh, 65% renewal; fresh growth 41% stated

Current ROE 11.8% (last 4Q rolling); gap to 14-18% is 200-600 bps; no interim targets provided

103.2% Q1FY26 → 100.2% Q1FY27; driven by 380 bps loss ratio improvement minus 90 bps expense ratio drag; loss ratio benefit from retail mix and pricing actions.

Market share up; retail growth 47.1% vs market 31.6%, 15.5 point outpace confirms Bharat strategy and distribution leverage working.

Flat growth Q1 vs prior positive growth; mgmt now refuses uneconomic business (pricing at claims-minus); structural de-rating of group unit until pricing normalizes.

11.8% rolling ROE reaffirmed to reach mid-high teens by FY29 (3 year horizon); no interim targets; leverage from operating leverage and expense ratio, not margin expansion.

38% Q1FY26 → 35.2% Q1FY27; exceeds prior 2-2.5% guidance; target 32-33% by full-year stabilization.

July in line with expectations; infection season will test; retail loss ratio benefited from new business, group from underwriting discipline; RI profit commission timing creates quarterly noise.

RI has profit commission booked in different quarters; no structural change. GST commission passed to distributors; ITC loss will normalize Q3. EOM improved 38% to 35.2%.

No change; same levers: diversified multi-channel, Bharat strategy Tier 2/3, same investment level 6 years. Target 8-10 bps faster than market on retail. Advisor expansion, new products (Reassure 3.0), AI-led productivity.

Target 70/30 retail/group mix maintained. Not averse to group; only issue is combined ratio not meeting threshold. Group pricing at 'claims minus' makes no economic sense. SME growing 50%+ but not offsetting B2B renewal losses.

Retail overall 46.5% growth; fresh 41%; both growing. July strong. Want 8-10% faster than market. Fresh 35% of retail GWP, renewal 65%. High single-digit annual price increase on renewals.

PPN guides to secondary care; 15-20% lower average claim size vs quaternary/tertiary for same treatment (e.g. cholecystectomy). Better SOP compliance reduces ICU abuse. Can flex to price competitiveness vs always lowering loss ratio.

Renewal loss ratio ~75%; fresh much lower implicitly. Pricing actions, PPN, mix shift to retail all contributed 380 bps LR improvement. July claims in line with plan.

CISR is amortized 1/365 and DAC basis; already normalized. Earnings slower than GWP; won't materially deteriorate H1 to H2. Expense reduction will offset any LR pressure. Infection is only abnormal risk.

₹250Cr NCD call due this year (raised 5 years back at 10.7% coupon, A rating). Now AAA rated. Evaluating options for refinance and growth plans. Haven't decided on amount yet.

Conservative strategy maintained. AIF 12-15% yield, now 4% of AUM (max 5% regulatory limit). Mostly performing credit AIFs; open to pedigreed special situation AIFs. Nifty ETF allocation at 3.5%. No direct equity discussion yet.

29% is earned premium (amortized 1/365 from last year and multiyear policies back 2-3 years). GWP 23% is fresh written; earned is lagged and depends on mix of multiyear policies in Q1 last year vs this year.

75% acceptable; expenses only ~20%; implies 55% contribution margin. Annual high single-digit price increases applied annually to renewal book to keep LR flat.

38% to 35.2% is 2.8% improvement, exceeds 2-2.5% guide. Will stabilize 32-33%. ROE 11.8% now; guided mid-high teens by FY29; smooth trajectory amortized, barring infections.

Q1 achieved 15.5 point outpace (47.1% vs 31.6% market); reaffirmed multi-channel, Bharat Tier 2/3, advisor expansion, product innovation (Reassure 3.0)

Current 11.8% (last 4Q rolling); gap 200-600 bps to target; no interim FY27/FY28 ROE targets given; relies on smooth amortized trajectory and operating leverage

Q1 at 35.2% (improved from 38%); GST ITC normalization Q3 onwards should accelerate convergence to 32-33% range

NCD ₹250Cr call option due this year (5-year-old); AAA rating now supports cheaper refinance; amount and timing TBD based on growth capex needs next 2 years

PAT ₹137.8Cr down 60% QoQ despite 8% revenue growth signals seasonal or investment income swings. CISR 100.2% is break-even; entire margin from 7.2% investment yield on ₹10Cr AUM, vulnerable to rate cycle.

Group growth flat Q1; mgmt refuses uneconomic large-account business; 'market pricing at claims minus'. Group ~30% of target mix; flat growth limits leverage and caps overall growth to retail-only trajectory.

ROE 11.8% vs FY29 target mid-high teens (14-18%); gap 200-600 bps over 3 years. No interim targets. Relies on smooth 1/365 amortized trajectory and expense leverage; inflation or loss ratio drift could slow path.

Monsoon (Aug-Oct) brings dengue, malaria, infections; loss ratios typically spike. Mgmt said 'infection season will start in some time; will update next quarter.' No proactive hedging disclosed.

Renewal retail loss ratio 75% with only high-single-digit annual price increases. If medical inflation >5% or claim severity trends worse, 75% loss ratio could deteriorate, squeezing profitability.